MarketBeat reports average 'Sell' rating for Curanex Pharmaceuticals Inc.
1 report, 1 independent
Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported that Curanex Pharmaceuticals Inc. currently holds an average rating of “Sell.” The company experienced a significant rise in short interest during September, growing from 449 shares on August 31st to 2,823 shares by September 15th. The stock traded up $0.28 during mid-day trading on Friday, reaching $4.72.
From themarketsdaily.com
Why it matters
The increase in short interest suggests market skepticism regarding Curanex Pharmaceuticals Inc. despite the stock trading higher. MarketBeat's rating reflects analyst sentiment that the company, a developmental stage pharmaceutical firm, is currently risky.
From themarketsdaily.com
Who's involved
- MarketBeatReported the average rating and market performance of Curanex Pharmaceuticals Inc.
- NasdaqHosts the listing for Curanex Pharmaceuticals Inc.
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
Related events
- MarketBeat reported an average stock rating for Superior Group of Companies.
- MarketBeat reported analyst ratings related to Citigroup.
- MarketBeat reported company consensus ratings for Sanuwave Health Inc. on August 30, 2026.
- MarketBeat reported average stock rating for I-Mab on September 9, 2026.
- MarketBeat reported an average stock rating for ATA Creativity Global.